Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer
一项针对转移性三阴性乳腺癌患者的MEK抑制剂曲美替尼单药治疗及联合AKT抑制剂GSK2141795/uprosertib治疗的II期研究
期刊:Breast Cancer Research and Treatment
影响因子:3
doi:10.1007/s10549-024-07551-z
Prasath, Vishnu; Boutrid, Hinda; Wesolowski, Robert; Abdel-Rasoul, Mahmoud; Timmers, Cynthia; Lustberg, Maryam; Layman, Rachel M; Macrae, Erin; Mrozek, Ewa; Shapiro, Charles; Glover, Kristyn; Vater, Mark; Budd, G Thomas; Harris, Lyndsay; Isaacs, Claudine; Dees, Claire; Perou, Charles M; Johnson, Gary L; Poklepovic, Andrew; Chen, Helen; Villalona-Calero, Miguel; Carson, William; Stover, Daniel G; Ramaswamy, Bhuvaneswari